Replies to post #39451 on Cytodyn Inc (CYDY)

[ClosetInvestor]

The prostrate cancer test should be licensed as well and bring in a decent amount of revenues each year. Those revenues can be used to help push leronlimab through other trials and, like you said, possibly build a sales and marketing team. I too like the idea of CYDY keeping the licensing rights for some indications as that’s mean more revenues and more value for the stockholders.

[Fortuno]

What I did not like:

Licensing could happen this year (doesn’t sound like they’re close to a deal, ergo another Paulson raise);
Not a single word about first injection TNBC (I’ve gotten the feeling that they’re going to do the 8 preclinicals first; don’t like that);
The highly irritable and distractable “music” in the background.

Maybe it’s just me and my state of mind, but it made me just feel like: more delays and Paulson raises soon.

I do get them having to take steps to market and sell L on their own, but frankly I do not hope so, they don’t have the expertise and others have tried thinking they could do it on their own and failed terribly.